Articles From: 2014/9/12 - Aveva sinks; E.ON climbs: Europe's big stock movers to - Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA™ (Daclizumab High-Yield Process)


2014/9/12
By Sara Sjolin, MarketWatch LONDON (MarketWatch) -- Here are some of the companies whose shares made notable moves in European trade on Friday.
Sign-up for 2014/9/12 - Aveva sinks; E.ON climbs: Europe's big stock movers investment picks
http://media.marketwire.com/attachments/201210/90690_Cisco_logo.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1144118&ProfileId=051205&sourceType=1 AMSTERDAM, THE NETHERLANDS --
Sign-up for - Transformation Through Innovation -- Cisco at IBC 2014 investment picks
First-in-FPGA Solutions for both H.265 (HEVC) and SMPTE 2059 Allowing Precise Synchronization of IP-enabled UHD Infrastructure AMSTERDAM , Sept.
Sign-up for - Altera Demonstrates Advanced SMPTE Solutions for IP-Based UHD Infrastructure at IBC 2014 investment picks
Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced that the United States Food and Drug Administration (FDA) approved Baxter’s subcutaneous treatment for adult patients with primary immunodeficiency (PI), HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]. HYQVIA is the first subcutaneous immune globulin (IG) treatment approved for PI patients with a dosing regimen requiring only one infusion up to once per month (every three to four weeks) and one injection site per infusion to deliver a full therapeutic dose of IG.
Sign-up for - FDA Approves Baxter’s HYQVIA for Treatment of Adults with Primary Immunodeficiency investment picks
2014/9/12
By Quentin Fottrell, MarketWatch 1.
Sign-up for 2014/9/12 - UPDATE: 10 things Apple won't say investment picks
2014/9/12
S&P Dow Jones Indices Announces Changes to the S&P/TSX Canadian Indices Canada NewsWire The Annual Review of the S&P/TSX SmallCap Index TORONTO , Sept.
Sign-up for 2014/9/12 - S&P Dow Jones Indices Announces Changes to the S&P/TSX Canadian Indices investment picks
Luxoft Holding, Inc (NYSE:LXFT), a leading provider of software development services and innovative IT solutions to a global client base, today announced results of the Annual Meeting of Shareholders held on September 12, 2014.
Sign-up for - Luxoft Announces Results of the Annual Meeting of Shareholders investment picks
On September 8, 2014, Cal Dive International, Inc. (NYSE:DVR) (the “Company”) received notice from the New York Stock Exchange that it does not currently satisfy the minimum share price standard for continued listing of the Company’s common stock.
Sign-up for - Cal Dive Receives Continued Listing Standards Notice from the New York Stock Exchange investment picks
LOS ANGELES, Sept.
Sign-up for - Wilshire Bancorp Declares $0.05 Cash Dividend investment picks
By Sue Chang and Victor Reklaitis, MarketWatch SAN FRANCISCO (MarketWatch)--These are the stocks making notable moves in the market on Friday.
Sign-up for - UPDATE: Yahoo gets Alibaba boost, Ulta surges on earnings investment picks
2014/9/12
NEWARK, Del., Sept.
Sign-up for 2014/9/12 - New data shows Navient continues to prevent more student loan defaults investment picks
2014/9/12
CIBC recognized for Best Leadership Development Program by Brandon Hall Group Canada NewsWire Receives accolades for best-in-class leadership training programs and learning tools TORONTO , Sept.
Sign-up for 2014/9/12 - CIBC recognized for Best Leadership Development Program by Brandon Hall Group investment picks
2014/9/12
Corindus Vascular Robotics, Inc. [OTCQB: CVRS], a leading developer of precision vascular robotics (“Corindus” or the “Company”), announced today that it entered into a Securities Purchase Agreement pursuant to which the Company will issue and sell to certain accredited investors an aggregate of 10,666,570 shares of the Company’s Common Stock in a private placement at a purchase price of $2.50 per share, resulting in aggregate gross proceeds to the Company of approximately $26.6 million.
Sign-up for 2014/9/12 - Corindus Vascular Robotics, Inc. Closes Private Placement for $26.6 Million investment picks
2014/9/12
The U.S. joined the European Union in expanding sanctions to target Russian Arctic and shale-oil projects and further limit financing to Russian state-controlled companies, a move to put pressure on Moscow as Ukraine negotiates a long-term peace plan and closer ties to the E.U. The energy sanctions announced Friday, widely expected in recent days, will prevent Western energy firms from providing technology and services -- other than financial services --
Sign-up for 2014/9/12 - U.S., EU Widen Sanctions on Russia investment picks
By Claudia Assis, MarketWatch SAN FRANCISCO (MarketWatch)--Shares of Polypore International Inc. rose nearly 2% Friday after analysts at Cowen and Co.
Sign-up for - Polypore rides electric-car interest, gets nod from Cowen investment picks
2014/9/12
Customers can now earn AIR MILES reward miles and redeem with AIR MILES cash at Sobeys, IGA and Sobeys Liquor stores in Western Canada Canada NewsWire EDMONTON , Sept.
Sign-up for 2014/9/12 - Customers can now earn AIR MILES reward miles and redeem with AIR MILES cash at Sobeys, IGA and Sobeys Liquor stores in Western Canada investment picks
Tech stocks had a rough go of it in early trading Friday, with losses coming from sector leaders Apple Inc. (AAPL) , Amazon.com Inc. (AMZN) , Google Inc. (GOOG) and Microsoft Corp.
Sign-up for - Apple, Amazon among tech stocks with early losses investment picks
2014/9/12
By Josie Cox and Anjani Trivedi The U.S. dollar has been climbing for nine weeks, marking its longest rally in 17 years, spurred by expectations that the Federal Reserve could raise interest rates next year, in a divergence from other major central banks that are still in easing mode.
Sign-up for 2014/9/12 - U.S. Dollar Marks Longest Rally in 17 Years investment picks
2014/9/12
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G021577-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/9/11/11G021577/ce473b96ba1225a7e84148cb80fba4f0-294299329671.jpg WEST PALM BEACH, FL--(Marketwired - September 12, 2014) - FastFunds Financial Corporation ("FastFunds" or the "Company") (PINKSHEETS: FFFC) and its wholly-owned subsidiaries, Cannabis Angel, Inc., and The 420 Development Corporation, are pleased to announce that Brawnstone Security, LLC.
Sign-up for 2014/9/12 - Brawnstone Security, LLC. Awarded Additional Security Services Contract investment picks
2014/9/12
Sprint (S) for the first time ever will give customers looking to buy the new iPhone an exclusive no-contract plan.
Sign-up for 2014/9/12 - Sprint ditches contracts for iPhone 6 investment picks
New Topics Include Electronic Components and Choice of Technology Tracks GREENVILLE, S.C., Sept.
Sign-up for - KEMET Institute of Technology Series Begins 31st Season investment picks
Frontier Communications Corporation (NASDAQ:FTR) is scheduled to participate in the Bank of America Merrill Lynch 2014 Media, Communications and Entertainment Conference on Tuesday, September 16, 2014.
Sign-up for - Frontier Communications Corporation to Participate in Investor Conference investment picks
Today Biogen Idec (NASDAQ: BIIB) and AbbVie (NYSE: ABBV) announced the full results from the Phase 3 DECIDE clinical trial, which show ZINBRYTA™ (daclizumab high-yield process), dosed subcutaneously once a month, demonstrated a statistically significant improvement in reducing disease activity in people with relapsing-remitting multiple sclerosis (RRMS) compared to AVONEX ® (interferon beta-1a). These results are being presented at the Sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS) in Boston.
Sign-up for - Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA™ (Daclizumab High-Yield Process) investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: 2014/9/12 - Aveva sinks; E.ON climbs: Europe's big stock movers to - Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA™ (Daclizumab High-Yield Process)
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices